The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2,002.00
Bid: 2,006.00
Ask: 2,008.00
Change: -10.00 (-0.50%)
Spread: 2.00 (0.10%)
Open: 2,014.00
High: 2,024.00
Low: 1,994.00
Prev. Close: 2,012.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Hikma announces agreement with Vectura

8 Nov 2018 09:44

RNS Number : 7663G
Hikma Pharmaceuticals Plc
08 November 2018
 

London, 8 November 2018 - Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody's / BB+ S&P, both stable) today announces that it has signed an agreement with Vectura Group plc (Vectura) for the global development and commercialisation of generic versions of GSK's Ellipta® portfolio, utilising Vectura's proprietary Open-Inhale-Close dry powder inhaler device.

Siggi Olafsson, Chief Executive Officer of Hikma, said: "The generic respiratory market is a key area of pipeline focus for Hikma. This agreement leverages the investment we have made and the experience we have gained through our generic Advair Diskus® programme. By strengthening and expanding our partnership with Vectura, we will develop a pipeline of complex respiratory products that will enable us to deliver sustainable long-term growth."

A significant opportunity to bring complex respiratory products to market

Following interactions with the US FDA, Vectura and Hikma believe the Open-Inhale-Close dry powder inhaler device has the potential to be developed as an AB-rated substitutable drug-device combination for generic versions of the GSK Ellipta® portfolio. This presents a significant opportunity, with net sales for Ellipta® products in the US projected to be $4 billion by 2024 and approximately $5.5 billion globally1.

The Open-Inhale-Close dry powder inhaler programme includes the development of AB-rated substitutable generics of up to five GSK respiratory medicines. Hikma and Vectura have agreed to develop and commercialise at least three of the portfolio products. A substitutable generic version of Breo® Ellipta® (fluticasone furoate and vilanterol trifenatate) will be prioritised for the first wave of development. Pharmaceutical and device development work has progressed in parallel with partnering discussions. The new device is an evolution of Vectura's lever-operated multi-dose (LOMI) device and builds on Vectura and Hikma's shared experience with the generic Advair Diskus® programme, enabling accelerated development under this new agreement.

Financial considerations

Upon signing, Hikma will make an upfront payment of $15 million to Vectura. Vectura will be responsible for, and fund, initial device and formulation development. Hikma will be responsible for clinical development, regulatory submission and commercialisation. Upon transfer of the first product to Hikma's manufacturing facility to enable clinical manufacturing, Hikma will make a $5 million milestone payment to Vectura. Thereafter, Hikma will make milestone payments of up to $75 million at various stages of development, including the delivery of pharmacokinetic clinical trials, pivotal clinical trials, ANDA submissions and FDA approvals. On approval, Hikma will pay a share of distributable net profit of up to a mid-teen percentage for each portfolio product. Hikma will also pay sales milestones on the achievement of certain cumulative net sales targets. Vectura will contribute up to $70 million towards Hikma's development activities for the portfolio. Vectura's contribution to the development costs will be deferred and made through a reduced profit share mechanism following commercial launch of the first product.

1Global Data, October 2018

-- ENDS -

Enquiries

Hikma Pharmaceuticals PLC

Susan RingdalEVP, Strategic Planning and Global Affairs

+44 (0)20 7399 2760/ +44 7776 477050

uk-investors@hikma.com

 

 

FTI Consulting

Ben Atwell/Brett Pollard

+44 (0)20 3727 1000

 

About Hikma

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. We're a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner in the MENA region, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit www.hikma.com.

 

 

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAUGGWCGUPRUBR
Date   Source Headline
1st Jun 201811:34 amRNSTotal Voting Rights
30th May 20183:20 pmRNSDirector/PDMR Shareholding
30th May 20189:00 amRNSHikma launches Methylergonovine Maleate Tablets
23rd May 201810:20 amRNSDirector/PDMR Shareholding
18th May 20181:01 pmRNSAGM Results
18th May 20187:00 amRNSTrading Statement
17th May 20181:45 pmRNSDirector/PDMR Shareholding
17th May 20181:10 pmRNSDirector/PDMR Shareholding
15th May 20182:26 pmRNSDirector/PDMR Shareholding
3rd May 20189:00 amRNSHikma launches Methotrexate Injection
1st May 20181:38 pmRNSTotal Voting Rights
26th Apr 20181:40 pmRNSHolding(s) in Company
25th Apr 201810:41 amRNSBlock listing Interim Review
24th Apr 20189:00 amRNSHikma expands licensing agreement with Rovi
20th Apr 20189:00 amRNSHikma launches Dexrazoxane for Injection
19th Apr 201812:00 pmRNSAnnual Financial Report and Notice of AGM
10th Apr 20182:34 pmRNSDirector/PDMR Shareholding
3rd Apr 201811:19 amRNSTotal Voting Rights
29th Mar 20189:00 amRNSHikma launch-Palonosetron Hydrochloride Injection
20th Mar 20189:00 amRNSHikma has launched Ritonavir Tablets USP
19th Mar 20183:50 pmRNSDirector/PDMR Shareholding
14th Mar 20187:00 amRNSFinal Results
12th Mar 20187:00 amRNSUpdate status on ANDA for generic Advair Diskus®
9th Mar 20189:21 amRNSBlock Listing Application
27th Feb 201812:23 pmRNSNotice of Results
20th Feb 20187:00 amRNSSigurdur Olafsson appointed CEO of Hikma
13th Feb 20184:43 pmRNSHolding(s) in Company
8th Feb 201812:41 pmRNSDirector/PDMR Shareholding
8th Feb 201812:39 pmRNSDirector/PDMR Shareholding
8th Feb 201812:37 pmRNSDirector/PDMR Shareholding
26th Jan 20184:56 pmRNSHolding(s) in Company
17th Jan 20185:22 pmRNSHolding(s) in Company
15th Jan 20188:00 amRNSHikma Appoints Dr. Surendera Tyagi
4th Jan 201811:19 amRNSTotal Voting Rights
19th Dec 20179:00 amRNSHikma reaches licensing agreement with Celltrion
13th Dec 20179:00 amRNSHikma- Dihydroergotamine Mesylate Injection, USP
12th Dec 20179:59 amRNSHolding(s) in Company
11th Dec 20179:33 amRNSHolding(s) in Company
1st Dec 20179:28 amRNSTotal Voting Rights
30th Nov 20175:47 pmRNSHikma Ventures- $20.5m Series C round for Prognos
28th Nov 201710:24 amRNSAnnouncement
27th Nov 20171:38 pmRNSHikma Ventures invests in Biolinq
22nd Nov 20179:32 amRNSHolding(s) in Company
20th Nov 20179:32 amRNSHolding(s) in Company
14th Nov 20178:47 amRNSHolding(s) in Company
14th Nov 20177:00 amRNSHikma Acquires Products from Boehringer Ingelheim
8th Nov 20174:45 pmRNSHolding(s) in Company
2nd Nov 20172:51 pmRNSHolding(s) in Company
1st Nov 201711:43 amRNSTotal Voting Rights
30th Oct 20179:26 amRNSHikma launches Pantoprazole Sodium for Injection

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.